KaliVir Immunotherapeutics, LLC

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs

Cancer vaccines have gained in prominence over the last couple of decades, as the emergence of immuno-oncology has validated the immune system’s essential role in maintaining healthy cell division. Th

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Innoviva Acquisition Of Entasis Leaves